For the Inventor, By the Inventor

Enter assignee name

San Diego, CA, United States of America

Crinetics Pharmaceuticals, Inc.

USPTO Granted Patents = 33

EPO Patents = 10

Trademarks = 5

Forward Citations = 125

Loading Chart...

Loading Chart...

32 inventors (with patents filed for the assignee):

Yunfei Zhu (25 out of 27 patents)

Jian Zhao (18 out of 52 patents)

Sangdon Han (18 out of 40 patents)

4. Sun Hee Kim (18 out of 24 patents)

5. Shimiao Wang (15 out of 15 patents)

6. Jayachandra P Reddy (4 out of 6 patents)

7. Mahmoud Mirmehrabi (3 out of 17 patents)

8. Mi Chen (3 out of 29 patents)

9. Ian Yates (2 out of 6 patents)

10. Gerald Burke (2 out of 2 patents)

11. Hannah Bulovsky (2 out of 2 patents)

12. Kyle Kyburz (2 out of 2 patents)

13. Clayton Tyler (2 out of 2 patents)

14. Yuxin Zhao (2 out of 9 patents)

15. Joseph Pontillo (2 out of 17 patents)

Core Competencies:

Somatostatin Modulators

Melanocortin Receptor Antagonists

Crystalline Forms

Nonpeptide Agonists

Hepatic Impairment

Therapeutics

Piperidine Compounds

Compositions

Formulations

Targeted Treatments

Disease Management

Process Development

33 patents: Sort by Forward Citations

1. 12617767 - Crystalline forms of somatostatin modulators (2026-05-05),

2. 12600709 - Nonpeptide somatostatin type 5 receptor agonists and uses thereof (2026-04-14),

3. 12492181 - Gem-disubstituted piperidine melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof (2025-12-09),

4. 12479828 - Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof (2025-11-25),

5. 12479825 - Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof (2025-11-25),

6. 12466829 - Spirocyclic piperidine melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof (2025-11-11),

7. 12280046 - Melanocortin subtype-2 receptor (MC2R) antagonist for the treatment of disease (2025-04-21),

8. 12208092 - Compositions and methods for administering paltusotine to patients with hepatic impairment (2025-01-28),

9. 12134610 - Somatostatin subtype-2 receptor (SST2R) targeted therapeutics and uses thereof (2024-11-05),

10. 11957674 - Formulations of a somatostatin modulator (2024-04-16),

11. 11834462 - Somatostatin modulators and uses thereof (2023-12-05),

12. 11773076 - Crystalline forms of a somatostatin modulator (2023-10-03),

13. 11608335 - Somatostatin modulators and uses thereof (2023-03-21),

14. 11566015 - Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof (2023-01-31),

15. 11479540 - Nonpeptide somatostatin type 5 receptor agonists and uses thereof (2022-10-25),

Crinetics Pharmaceuticals, Inc. is a biopharmaceutical company based in San Diego, California, focused on developing innovative therapies for endocrine diseases and disorders. The company specializes in the discovery and development of novel small molecule therapeutics that target specific hormonal pathways, aiming to address unmet medical needs in conditions such as acromegaly and Cushing's disease. Crinetics is committed to advancing its proprietary drug candidates through clinical development to improve patient outcomes.

Profile summary based on public USPTO records.

Company Badge

USPTO Data Jan 1 1976 - Oct 6 2026

Crinetics Pharmaceuticals, Inc.

33 Patents

#192 in San Diego, CA

#2,460 in California

#10,297 in US

#20,130 in the World

San Diego, CA, United States of America

Crinetics Pharmaceuticals, Inc.

Forward Citations = 125

32 inventors:

Yunfei Zhu (25 out of 27 patents)

Jian Zhao (18 out of 52 patents)

Sangdon Han (18 out of 40 patents)

4. Sun Hee Kim (18 out of 24 patents)

5. Shimiao Wang (15 out of 15 patents)

Please report any incorrect information to [email protected]

Loading…